DENTSPLY SIRONA (NASDAQ:XRAY) Updates FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.400-1.500 for the period, compared to the consensus estimate of 1.420. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $12.12 on Friday. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. The firm has a market cap of $2.43 billion, a P/E ratio of -4.41, a P/E/G ratio of 1.57 and a beta of 0.85. The firm has a 50 day simple moving average of $11.77 and a 200 day simple moving average of $11.89. DENTSPLY SIRONA has a fifty-two week low of $9.40 and a fifty-two week high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.74% and a negative net margin of 14.99%.The business’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts predict that DENTSPLY SIRONA will post 1.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on XRAY. Mizuho cut their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. UBS Group lowered their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday. Citigroup began coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price on the stock. Finally, Piper Sandler lifted their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $13.54.

Insiders Place Their Bets

In other news, Director Brian P. Mckeon acquired 10,000 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was acquired at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael J. Barber acquired 15,175 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the purchase, the director directly owned 55,943 shares in the company, valued at $552,716.84. This trade represents a 37.22% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 35,160 shares of company stock worth $351,179. Company insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA News Roundup

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Adjusted earnings exceeded expectations: Q2 EPS was $0.52, above analyst estimates ranging from $0.35 to $0.36 and matching the year-ago result. Revenue of $898 million also surpassed the roughly $890 million consensus. Dentsply International Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Margins improved: Management highlighted better margins during the quarter, helping offset softer demand and supporting the earnings beat. The Wellspect business was a key sales-growth contributor. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Neutral Sentiment: Full-year EPS guidance was maintained: DENTSPLY SIRONA reiterated 2026 adjusted EPS guidance of $1.40 to $1.50, which brackets the approximately $1.42 analyst consensus. DENTSPLY SIRONA Second-Quarter 2026 Results
• Negative Sentiment: Sales declined year over year: Q2 revenue fell 4.1%, as weakness in the company’s core dental business outweighed growth at Wellspect. This suggests that broader dental-market demand and utilization remain pressured. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Negative Sentiment: Revenue guidance was cautious: The company forecast 2026 revenue of $3.5 billion to $3.6 billion, with the midpoint below the $3.6 billion consensus estimate. Investors appear to be prioritizing the weak organic-sales trend and outlook over the quarterly EPS beat.

Hedge Funds Weigh In On DENTSPLY SIRONA

Institutional investors have recently modified their holdings of the business. AQR Capital Management LLC grew its stake in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Armistice Capital LLC boosted its holdings in DENTSPLY SIRONA by 1,044.0% during the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after purchasing an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after purchasing an additional 4,003,606 shares in the last quarter. Goldman Sachs Group Inc. grew its position in DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in DENTSPLY SIRONA by 1,032.5% in the 4th quarter. Marshall Wace LLP now owns 2,236,786 shares of the medical instruments supplier’s stock valued at $25,566,000 after buying an additional 2,039,280 shares during the last quarter. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.